Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 200 Barr Harbor Dr Ste 400 WEST CONSHOHOCKEN PA 19428-2978 |
Tel: | N/A |
Website: | https://www.madrigalpharma.com |
IR: | See website |
Key People | ||
Bill Sibold President, Chief Executive Officer, Director | Mardi C. Dier Chief Financial Officer, Senior Vice President | Rebecca A. Taub President of Research and Development, Chief Medical Officer, Director |
Brian J. Lynch Senior Vice President, General Counsel | Ronald Filippo Chief Information Officer | Carole Huntsman Chief Commercial Officer | Robert Waltermire Chief Pharmaceutical Development Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Madrigal Pharmaceuticals Inc revenues was not reported. Net loss increased 27% to $373.6M. Higher net loss reflects G & A increase from $30.4M to $79.3M (expense), R & D increase of 9% to $251.5M (expense), Stock-based Compensation in SGA increase of 63% to $28.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$17.23 to -$19.99. |
Employees: | 376 as of Feb 22, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,819M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$379.97M as of Dec 31, 2023 |
Net annual income (TTM): | -$373.63M as of Dec 31, 2023 |
Free cash flow (TTM): | -$325.71M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 20,625,427 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |